Amarin stock jumps on patent progress for blockbuster hopeful; OncoGenex seeks $46.8M in stock sale;


 @FierceBiotech: Analysis on biotech VC math by via @LifeSciVC explains why smaller funds make sense. Report | Follow @FierceBiotech

 @JohnCFierce: Ian Read's comp jumped 44%, to $25 million, when he get the big promo at Pfizer. Item | Follow @JohnCFierce

 @RyanMFierce: Active Biotech up on news that partner Teva plans to seek European OK for MS drug $ACTI $TEVA. Story | Follow @RyanMFierce

@FierceMedDev: Sanofi to buy U.S. medical device company Pluromed via @Reuters. News | Follow @FierceMedDev

> Drug developer Amarin's ($AMRN) stock jumped today upon renewed confidence that it was making progress securing patent protections for AMR10, its omega-3 drug that's viewed as a potential blockbuster. Item

> Medco Health Solutions reports that its analyses show that drugs for heartburn and other ailments can hurt the efficacy and boost the toxicity of certain cancer meds. Report

> OncoGenex Pharmaceuticals ($OGXI) said today that it plans to raise $46.8 million through a stock offering, which follows the Bothell, WA-based company's announcement last week that it's expanding a trial for its lead drug for prostate cancer. OncoGenex release

> Threshold Pharmaceuticals ($THLD) has garnered orphan status from the European Commission for its experimental med TH-302, which is a hypoxia-targeted drug for treating soft tissue sarcoma. Article

Pharma News

 @FiercePharma: EMA orders production of cancer meds Caelyx (aka Doxil) and Ceplene to be moved from Ben Venue plant $JNJ $EPCT. News | Follow @FiercePharma

> Novartis persuades NICE to endorse Gilenya. Article

> Setting new course, Pfizer CEO gets 44% pay hike. Item

> Hamburg says FDA needs more leeway to combat drug fakes. News

> Can European pharma's cash flow cover buyback plans? Story

> Mylan bows out of Rottapharm bidding. Item

And Finally… Their advances spurned by their female counterparts, male fruit flies hit the proverbial bottle and eat alcohol-laden foods. Article

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.